Diabetes Prevention Program in Schizophrenia [DPPS]
Recruitment status was: Recruiting
Behavioral: Modified diabetes prevention protocol & Metformin
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Primary Purpose: Prevention
|Official Title:||A Five Year, Prospective, Randomized, Blinded, Controlled Trial Comparing the Efficacy of a Modified Diabetes Prevention Protocol and the Standard Comprehensive Outpatient Care in Lowering the Incidence of New Onset Diabetes Among People Treated for Schizophrenia and Are at Risk to Develop Type II Diabetes Mellitus.|
- 1. Adherence/ability to run as designed /recruitment
- 2. Impact on modifiable diabetes risk factors
- 3. Impact on incidence of diabetes
- 1. Adherence Rates for Diet, Exercise, Meds
- 2. Changes in lifestyle, Changes in eating patterns, Changes in activity patterns
- 3. Sustained changes in eating & activity patterns
|Study Start Date:||February 2005|
|Estimated Study Completion Date:||January 2009|
- From large international RCT studies, Type 2 Diabetes can be prevented / delayed for overweight, pre-diabetic individuals by making basic lifestyle changes (regular moderate exercise, healthy eating habits) and using metformin or other insulin resistance inhibitor.
- Individuals with schizophrenia are in particular need of preventative intervention and conventional approaches do not match their needs.
- Research has not examined how to facilitate lifestyle changes in the lives of individuals with schizophrenia.
We need to…
- Develop and evaluate innovative diabetes prevention strategies tailored to meet the needs of individuals with schizophrenia.
- Research how to make it work for pre-diabetic individuals being treated for schizophrenia.
The effectiveness of the novel intervention will be tested using a prospective, randomized, controlled clinical trial. A multi-factorial design enables a 2 x 2 analysis of the independent effects of three interventions – a tailored lifestyle modification program, metformin, and the standard conventional intervention. There is no anticipated interaction effect between metformin and lifestyle interventions. Clients currently treated for schizophrenia at a community outpatient clinic will be screened for diabetes, and those who fulfill the inclusion criteria, and give written consent, following a three week run-in period, will be randomized to one of four groups to receive either: the experimental intervention with placebo, the experimental intervention with metformin or the conventional intervention with placebo or conventional intervention with metformin.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00182494
|Contact: Lakshmi P Voruganti, MD||905-522-1155 ext firstname.lastname@example.org|
|Contact: Susan Strong, MScemail@example.com|
|Hamilton, Ontario, Canada|
|Contact: Lakshmi P Voruganti, MD 905-522-1155 ext 6355 firstname.lastname@example.org|
|Contact: Susan Strong, MSc 905 522 1155 email@example.com|
|Principal Investigator: Lakshmi P Voruganti, MD|
|Principal Investigator:||Lakshmi P Voruganti, MD||McMaster University|